Human Parathyroid Hormone 1-34 Prevents Bone Loss in Experimental Biliary Cirrhosis in Rats

Gastroenterology

Volumn 134, Issue 1, 2008, Pages 259-267

  Dresner Pollak, Rivka ^a   Gabet, Yankel ^b   Steimatzky, Arza ^c   Hamdani, Gilad ^c   Bab, Itai ^b   Ackerman, Zvi ^a   Weinreb, Miron ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE[1-34];

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILIARY CIRRHOSIS; BONE DENSITY; BONE DISEASE; BONE EXAMINATION; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; DISEASE MODEL; DRUG DOSE COMPARISON; DUAL ENERGY X RAY ABSORPTIOMETRY; EX VIVO STUDY; FEMUR; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TIBIA; TRABECULAR BONE; URINE LEVEL;

EID: 37349095256     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.10.025     Document Type: Article

References (39)

1. Solaymani-Dodaran M., Card T.R., Aithal G.P., et al. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 131 (2006) 1752-1757
2. Guanabens N., Pares A., Marinoso L., et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 85 (1990) 1356-1362
3. Guanabens N., Pares A., Ros I., et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42 (2005) 573-577
4. Menon K.V., Angulo P., Weston S., et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35 (2001) 316-323
5. Hodgson S.F., Dickson E.R., Wahner H.W., et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103 (1985) 855-860
6. Janes C.H., Dickson E.R., Okazaki R., et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95 (1995) 2581-2586
7. Hodgson S.F., Dickson E.R., Eastell R., et al. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 14 (1993) 819-827
8. Lindor K.D., Jorgensen R.A., Tiegs R.D., et al. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 33 (2000) 878-882
9. Zein C.O., Jorgensen R.A., Clarke B., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42 (2005) 762-771
10. Boone R.H., Cheung A.M., Girlan L.M., et al. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 51 (2006) 1103-1112
11. Ackerman Z., Weinreb M., Amir G., et al. Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease. Liver 22 (2002) 166-172
12. Weinreb M., Pollak R.D., and Ackerman Z. Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis. J Hepatol 40 (2004) 385-390
13. Hock J.M., Gera I., Fonseca J., et al. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 122 (1988) 2899-2904
14. Tada K., Yamamuro T., Okumura H., et al. Restoration of axial and appendicular bone volumes by h-PTH(1-34) in parathyroidectomized and osteopenic rats. Bone 11 (1990) 163-169
15. Dempster D.W., Cosman F., Parisien M., et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 14 (1993) 690-709
16. Gabet Y., Kohavi D., Muller R., et al. Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats. Osteoporos Int 16 (2005) 1436-1443
17. Turner R.T., Evans G.L., Lotinum S., et al. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 22 (2007) 64-71
18. Fox J., Miler M.A., Newman M.K., et al. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79 (2006) 262-272
19. Alexander J.M., Bab I., Fish S., et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16 (2001) 1665-1673
20. Finkelstein J.S., Klibanski A., Schaefer E.H., et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331 (1994) 1618-1623
21. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
22. Parfitt A.M., Drezner M.K., Glorieux F.H., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 (1987) 595-610
23. Fonseca V., Epstein O., Gill D.S., et al. Hyperparathyroidism and low serum osteocalcin despite vitamin D replacement in primary biliary cirrhosis. J Clin Endocrinol Metab 64 (1987) 873-877
24. Guichelaar M.M., Malinchoc M., Sibonga J., et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 36 (2002) 895-903
25. Bradbeer J.N., Arlot M.E., Meunier P.J., et al. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 37 (1992) 282-289
26. Jiang Y., Zhao J.J., Mitlak B.H., et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18 (2003) 1932-1941
27. Jilka R.L., Weinstein R.S., Bellido T., et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104 (1999) 439-446
28. Dobnig H., and Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 (1995) 3632-3638
29. Locklin R.M., Khosla S., Turner R.T., et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89 (2003) 180-190
30. Ma Y.L., Cain R.L., Halladay D.L., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142 (2001) 4047-4054
31. Frolik C.A., Black E.C., Cain R.L., et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33 (2003) 372-379
32. Murray T.M., Rao L.G., Divieti P., et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 26 (2005) 78-113
33. Pillai S., and Zull J.E. Production of biologically active fragments of parathyroid hormone by isolated Kupffer cells. J Biol Chem 261 (1986) 14919-14923
34. Segre G.V., Perkins A.S., Witters L.A., et al. Metabolism of parathyroid hormone by isolated rat Kupffer cells and hepatocytes. J Clin Invest 67 (1981) 449-457
35. Segre G.V., D'Amour P., Hultman A., et al. Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J Clin Invest 67 (1981) 439-448
36. D'Amour P., Huet P.M., Segre G.V., et al. Characteristics of bovine parathyroid hormone extraction by dog liver in vivo. Am J Physiol 241 (1981) E208-E214
37. Rouleau M.F., Warshawsky H., and Goltzman D. Parathyroid hormone binding in vivo to renal, hepatic, and skeletal tissues of the rat using a radioautographic approach. Endocrinology 118 (1986) 919-931
38. Kirch W., Hofig M., Ledendecker T., et al. Parathyroid hormone and cirrhosis of the liver. J Clin Endocrinol Metab 71 (1990) 1561-1566
39. Rittinghaus E.F., Juppner H., Burdelski M., et al. Selective determination of C-terminal (70-84) hPTH: elevated concentrations in cholestatic liver disease. Acta Endocrinol (Copenh) 111 (1986) 62-68